Biopharma's dual crisis: Diversity in trials and looming leadership gaps

The biopharmaceutical industry faces two pressing challenges: ensuring diverse representation in clinical trials and preparing for a wave of retirements. Regulators like the FDA and EMA are pushing for trials that better reflect real-world populations. At the same time, companies must address leadership gaps as millions of Baby Boomers leave the workforce by 2027. Regulatory bodies are making inclusive trial design a priority. Both the FDA and EMA have indicated that diversity in enrollment, design, and operations is no longer optional. However, concrete measures by leading companies to meet these expectations by 2026 remain unclear.

A broader shift is needed in how trials are structured. Intentional design and operational changes could help achieve better representation. Yet, without formal collaboration between firms and regulators, progress may stall.

Meanwhile, workforce changes are accelerating. Over 4 million Baby Boomers will retire each year until at least 2027. This exodus risks leaving gaps in leadership and institutional knowledge. Employers who fail to plan could lose up to 10% of their workforce in the next five years.

To counter this, companies are rethinking succession planning. Traditional reliance on informal networks often excludes marginalised groups. Instead, behavioural assessments can help identify employees with leadership potential, ensuring a more inclusive pipeline. Knowledge transfer to Gen Z and early-career staff is also becoming urgent. The industry stands at a crossroads. Without action, clinical trials may continue to lack diversity, and leadership shortages could deepen. Companies that adopt intentional strategies—both in trial design and talent development—will be better positioned to meet regulatory demands and maintain a skilled workforce.